

Date: 5 August 2022

**Re: Freedom of Information Request**  
**Ref: 258-2022**

Thank you for your email dated the 21<sup>st</sup> July 2022, requesting information in relation to colorectal cancer.

The information you require is as follows:

**Q1. Within your health trust, how many patients have been treated in the past 3 months (Apr - June 22) with the following agents for colorectal cancer [CRC]?**

<b>Aflibercept</b>	<b>0</b>
<b>Bevacizumab</b>	<b>&lt;5</b>
<b>Capecitabine</b>	<b>17</b>
<b>CAPIRI</b>	<b>7</b>
<b>CAPOX (Capecitabine + Oxaliplatin)</b>	<b>52</b>
<b>Cetuximab in combination with FOLFIRI</b>	<b>14</b>
<b>Cetuximab in combination with FOLFOX</b>	<b>&lt;5</b>
<b>Cetuximab not in combination with FOLFIRI or FOLFOX</b>	<b>25</b>
<b>Irinotecan only</b>	<b>9</b>
<b>FOLFIRI</b>	<b>0</b>
<b>FOLFOX</b>	<b>0</b>
<b>Fluorouracil (5FU) only</b>	<b>22</b>
<b>Oxaliplatin only</b>	<b>0</b>
<b>Panitumumab in combination with FOLFIRI</b>	<b>&lt;5</b>
<b>Panitumumab in combination with FOLFOX</b>	<b>&lt;5</b>
<b>Panitumumab not in combination with FOLFIRI or FOLFOX</b>	<b>18</b>
<b>Pembrolizumab</b>	<b>&lt;5</b>
<b>Nivolumab</b>	<b>7</b>
<b>Raltitrexed</b>	<b>0</b>
<b>Ramucirumab</b>	<b>0</b>
<b>Regorafenib</b>	<b>0</b>
<b>Sorafenib</b>	<b>0</b>
<b>Other SACT:</b>	
<b>Afatinib</b>	<b>&lt;5</b>

Atezolizumab	<5
Bicalutamide	<5
Capecitabine + Oxaliplatin	52
Capecitabine + RT	<5
Carboplatin + Etoposide	5
Carboplatin + Paclitaxel	<5
Cetuximab	25
Cetuximab + Irinotecan + Modified de Gramont	<5
Cetuximab + Modified de Gramont	8
Denosumab	<5
Docetaxel	<5
Encorafenib	8
Enzalutamide	<5
Epirubicin Cyclophosphomide	<5
Faslodex	<5
Gemcitabine + Capecitabine	<5
HYDROXYCARBAMIDE	<5
Ipilimumab	<5
Irinotecan + Modified De Gramont	44
Modified de Gramont	22
Osimertinib	<5
Oxaliplatin + Modified de Gramont	50
Oxaliplatin + Raltitrexed	<5
Palbociclib	<5
Panitumumab	18
Trastuzumab	<5
Trastuzumab Subcutaneous	<5
Trifluridine + Tipiracil	15
Triptorelin	<5
Vinorelbine with Carboplatin/Cisplatin	<5
Zoledronate	<5
Avatrombopag	0
Eltrombopag	0
Fostamatinib	0
Romiplostim	0
Avatrombopag	0
Mycophenolate mofetil	0
Rituximab	0
Surgery (splenectomy)	0

Where a small number of patients have been prescribed a treatment, the number of patients have been stated as <5, so as not to identify individual patients when combined with other datasets.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://forms.office.com/r/eLzHXi49Ea>



Kind Regards,

The Information Governance Team  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)

Version: 1.0  
Ref: ECGMFOIRE